Detail page

Knowledge Web

Person

Eva Rettinger (1976-)

Ärztin

Name	Eva Rettinger
Time	1976- (Date of birth and death)
Gender	weiblich
Academic degree	Dr. med. (Tübingen, Medizinische Fakultät) (2003) Dr. med. habil., Priv.-Doz. (Medizinische Fakultät der Goethe-Universität zu Frankfurt am Main) (2016)
Profession	Ärztin (characteristic profession)
Record type	Person
GND-Identifier	12867380X
Record ID	12867380X
Involved in show all CAR-Immunotherapies for the treatment of metastatic rhabdomyosarcomas Monitoring of circulating CAR T cells: validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following tisagenlecleucel Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy Retargeting of NK-92 cells against high-risk rhabdomyosarcomas by means of an ERBB2 (HER2/Neu)-specific chimeric antigen receptor ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma Long‐term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience The synergistic use of il-15 and il-21 for the generation of nk cells from cd3/cd19-depleted grafts improves their ex vivo expansion and cytotoxic potential against neuroblastoma: Perspective for optimized immunotherapy post haploidentical stem cell transplantation Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation Generierung, Identifizierung und Charakterisierung nicht alloreaktiver T-Lymphozyten zur adoptiven Immuntherapie im Rahmen allogener Stammzelltransplantationen Generierung, Identifizierung und Charakterisierung nicht alloreaktiver T-Lymphozyten zur adoptiven Immuntherapie im Rahmen allogener Stammzelltransplantationen

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Eva Rettinger (1976-)

CAR-Immunotherapies for the treatment of metastatic rhabdomyosarcomas

Monitoring of circulating CAR T cells: validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following tisagenlecleucel

Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy

Retargeting of NK-92 cells against high-risk rhabdomyosarcomas by means of an ERBB2 (HER2/Neu)-specific chimeric antigen receptor

ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma

Long‐term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience

The synergistic use of il-15 and il-21 for the generation of nk cells from cd3/cd19-depleted grafts improves their ex vivo expansion and cytotoxic potential against neuroblastoma: Perspective for optimized immunotherapy post haploidentical stem cell transplantation

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children

In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy

In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy

Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation

Generierung, Identifizierung und Charakterisierung nicht alloreaktiver T-Lymphozyten zur adoptiven Immuntherapie im Rahmen allogener Stammzelltransplantationen

Generierung, Identifizierung und Charakterisierung nicht alloreaktiver T-Lymphozyten zur adoptiven Immuntherapie im Rahmen allogener Stammzelltransplantationen